NMN and Endothelial Function: Vascular Aging

NMN Endothelial Function is one of the most compelling frontiers in vascular aging research. The cells lining your blood vessels — endothelial cells — are among the first to suffer as NAD+ levels decline with age, and restoring that NAD+ pool may help preserve their ability to regulate blood flow, blood pressure, and vascular repair. This article examines what the human evidence actually says about NMN supplementation and endothelial health, without overstating findings that remain preliminary.

What Endothelial Function Means for Aging

Endothelial cells form the inner lining of every blood vessel in your body. They produce nitric oxide (NO), a signaling molecule that relaxes vascular smooth muscle, maintains healthy blood pressure, and prevents platelets from clumping inappropriately. When endothelial function deteriorates — a condition called endothelial dysfunction — vessels become stiffer, less responsive, and more prone to atherosclerotic plaque formation.

Aging is the single strongest risk factor for endothelial dysfunction, independent of diet, smoking, or exercise habits. The mechanism is not merely wear and tear. Rather, it involves a progressive decline in cellular NAD+, the coenzyme that fuels sirtuins and PARPs, two enzyme families critical for endothelial stress responses and DNA repair. Gomes et al. (2013) demonstrated in Cell that declining NAD+ disrupts nuclear-mitochondrial communication, inducing a "pseudohypoxic" state where cells behave as if oxygen is scarce even when it is not. This metabolic confusion accelerates vascular aging at the cellular level.

The connection to NMN is straightforward on paper: NMN is a direct precursor to NAD+, and oral NMN supplementation has been shown to raise blood NAD+ levels in humans. Whether that rise translates into measurable improvements in endothelial function is the question the current evidence attempts to answer.

The Evidence Base

Human studies on NMN and vascular outcomes remain limited. No published randomized controlled trial to date has used flow-mediated dilation (FMD), pulse wave velocity (PWV), or other direct measures of endothelial function as a primary endpoint. What we have are indirect signals — metabolic, performance, and safety data — from a small set of human trials, plus a strong mechanistic rationale from animal and in vitro work.

Study	Design	Population	Dose & Duration	Key Relevant Findings
Yoshino et al. (2021)	Randomized, placebo-controlled	Prediabetic women (n=25)	250 mg/day NMN; 10 weeks	Improved muscle insulin sensitivity; no direct vascular endpoints measured
Igarashi et al. (2022)	Randomized, placebo-controlled	Healthy older men (n=42)	250–500 mg/day NMN; 12 weeks	Elevated blood NAD+ levels; altered muscle function; no vascular endpoints measured
Irie et al. (2020)	Open-label, single-arm	Healthy Japanese men (n=10)	100–500 mg/day NMN; single dose to 5 weeks	Confirmed oral bioavailability; no vascular endpoints measured
Liao et al. (2021)	Randomized, double-blind	Amateur runners (n=48)	300–1200 mg/day NMN; 6 weeks	Enhanced aerobic capacity (VO2 and ventilatory threshold); indirect cardiovascular benefit
Niu et al. (2023)	Randomized, placebo-controlled	Healthy middle-aged adults (n=8)	300 mg/day NMN; 8 weeks	Changes in serum metabolism and telomere length; no direct vascular endpoints measured

None of these studies directly measured endothelial function. However, the metabolic improvements seen in Yoshino et al. (2021) are relevant because insulin resistance and endothelial dysfunction are tightly coupled pathophysiologically. Improved muscle insulin sensitivity often precedes or parallels improvements in vascular reactivity. Similarly, Liao et al. (2021) showed dose-dependent improvements in aerobic capacity, which is impossible without some degree of preserved or enhanced vascular compliance and oxygen delivery — though the trial did not isolate endothelial mechanisms.

Igarashi et al. (2022) confirmed that chronic NMN supplementation elevates blood NAD+ in healthy older men, providing the pharmacokinetic bridge between supplementation and the coenzyme pool that endothelial cells depend upon. Irie et al. (2020) established that NMN is orally bioavailable in humans at doses ranging from 100 mg to 500 mg, with no serious adverse effects reported. Niu et al. (2023) added preliminary data on metabolic shifts and telomere length in a pre-aging population, though the sample size was very small.

The honest assessment: human data directly linking NMN supplementation to improved endothelial function is currently limited. The evidence is suggestive, not conclusive.

The Mechanism

Endothelial cells are highly metabolically active. They must maintain tight junctions, respond to shear stress, regenerate after injury, and produce nitric oxide on demand — all processes that require substantial ATP and, by extension, a healthy NAD+/NADH ratio.

NAD+ and Sirtuin Activation

Sirtuin 1 (SIRT1), an NAD+-dependent deacetylase, is highly expressed in endothelial cells. SIRT1 deacetylates and activates endothelial nitric oxide synthase (eNOS), the enzyme that produces nitric oxide from L-arginine. When NAD+ declines, SIRT1 activity falls, eNOS becomes hyperacetylated and dysfunctional, and NO production drops. This is one of the central mechanisms linking NAD+ depletion to endothelial dysfunction.

Gomes et al. (2013) showed that the pseudohypoxic state induced by NAD+ decline also stabilizes HIF-1α, a transcription factor normally degraded under normoxic conditions. Chronic HIF-1α activation in endothelial cells promotes a pro-inflammatory, pro-thrombotic phenotype — essentially, aged endothelium behaves like chronically hypoxic tissue even when perfused with oxygen-rich blood.

Mitochondrial Integrity

Endothelial mitochondria are not merely ATP factories. They participate in calcium signaling, redox sensing, and apoptosis regulation. NAD+ is required for mitochondrial fusion and for the activity of SIRT3, which deacetylates and protects mitochondrial proteins from oxidative damage. NMN-driven NAD+ restoration, in animal models, has been shown to improve mitochondrial density and function in aged vasculature — though human confirmation is pending.

Inflammation and Oxidative Stress

Aged endothelial cells exhibit elevated NF-κB signaling and increased reactive oxygen species (ROS) production. NAD+ supports PARP activity for DNA repair, but chronic PARP overactivation can deplete NAD+ and create a vicious cycle. By restoring NAD+ pools, NMN may theoretically rebalance this equation, reducing the inflammatory burden on vessel walls. Again, this is well supported in cell and rodent models; human vascular tissue data is not yet available.

What the Evidence Does Not Show

It is important to distinguish between raising blood NAD+ levels and improving endothelial function. Igarashi et al. (2022) and Irie et al. (2020) confirmed the former. None of the cited human trials confirmed the latter. The metabolic and performance benefits observed in Yoshino et al. (2021) and Liao et al. (2021) are genuine and clinically interesting, but they are not substitutes for direct vascular measures.

We also do not have long-term safety data beyond 12 weeks. Niu et al. (2023) used an 8-week protocol; Igarashi et al. (2022) ran for 12 weeks. The effects of years of continuous NMN supplementation on endothelial biology, platelet function, or vascular remodeling are unknown. Animal studies have generally been reassuring, but species differences in NAD+ metabolism and vascular physiology limit direct translation.

Dose-response relationships for vascular endpoints are entirely speculative in humans. Liao et al. (2021) tested 300 mg, 600 mg, and 1200 mg daily in runners and found dose-dependent effects on aerobic capacity, but this population was young, healthy, and exercise-trained. Whether older adults with existing endothelial dysfunction require higher or lower doses for vascular benefit is unknown.

Who Benefits Most

Based on the available evidence, the populations in whom NMN supplementation is most rational for vascular health are those with confirmed or high risk of endothelial dysfunction and age-related NAD+ decline. This includes:

• Older adults (50+) with normal or mildly impaired glucose tolerance, given the insulin sensitivity improvements seen in Yoshino et al. (2021). Insulin resistance and endothelial dysfunction share common pathways, and addressing one may support the other.
• Sedentary middle-aged adults beginning exercise programs, as suggested by Liao et al. (2021). NMN may enhance the vascular adaptations to aerobic training, though this specific interaction has not been tested directly.
• Individuals with metabolic syndrome or prediabetes, again extrapolating from the prediabetic population in Yoshino et al. (2021). These individuals have both endothelial dysfunction and NAD+ depletion as part of their pathophysiology.

Healthy young adults with normal endothelial function and high baseline NAD+ levels are the least likely to derive measurable vascular benefit from NMN, based on current evidence. The supplement is not a replacement for exercise, weight management, or blood pressure control — the interventions with the strongest proven impact on endothelial function.

Practical Takeaways

• Evidence is preliminary but directionally consistent. NMN raises blood NAD+ in humans and improves metabolic parameters that are linked to vascular health. Direct endothelial function trials have not yet been published.
• Dosing in human trials ranges from 250 mg to 1200 mg daily. Most studies showing benefits used 250–500 mg/day. For those considering supplementation, Bio:sudo NMN 1000mg provides a dose within the range studied, though individual needs vary.
• NMN is not a standalone vascular therapy. It should be viewed as a potential adjunct to exercise, dietary improvement, and standard cardiovascular risk management — not a replacement.
• Duration matters. The shortest trial showing metabolic benefit was 10 weeks. Expecting immediate changes in blood pressure or vessel stiffness is unrealistic based on current data.
• Safety profile appears favorable in short-term studies. No serious adverse events were reported in the cited human trials, but long-term data beyond 12 weeks is lacking.
• Quality and form matter. NMN is available in capsules, powders, and sublingual preparations. Human bioavailability data from Irie et al. (2020) used oral capsules; other forms have not been directly compared in peer-reviewed trials.

For readers interested in how NAD+ decline affects broader cardiovascular systems, see our article on NMN and Cardiovascular Health. The age-related drop in NAD+ is also covered in detail in NAD+ Decline by Age. A broader survey of the anti-aging supplement landscape, including where NMN fits relative to other compounds, is available in Anti-Aging Supplements: The Evidence.

Bottom Line

The mechanistic case for NMN supporting endothelial function is strong: NAD+ fuels the sirtuins and mitochondrial quality control pathways that keep vascular lining cells functional, and human trials confirm that oral NMN reliably raises blood NAD+ levels. However, no published human study has yet measured flow-mediated dilation, arterial stiffness, or other direct endothelial outcomes. The metabolic and performance benefits are real, but they are not proven vascular benefits. For now, NMN is a rational consideration for adults with age-related metabolic decline, not a proven therapy for endothelial dysfunction.

References

1. Yoshino M, et al. "Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women." Science. 2021;372(6547):1224–1229. [Source]
2. Igarashi M, et al. "Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men." npj Aging. 2022;8(1):5. [Source]
3. Irie J, et al. "Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men." Endocrine Journal. 2020;67(2):153–160. [Source]
4. Liao B, et al. "Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study." Journal of the International Society of Sports Nutrition. 2021;18(1):54. [Source]
5. Gomes AP, et al. "Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging." Cell. 2013;155(7):1624–1638. [Source]
6. Niu KM, et al. "The impacts of short-term NMN supplementation on serum metabolism, fecal microbiota, and telomere length in pre-aging phase." Nutrients. 2023;15(3):755. [Source]

---

---